Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing Collaboration

Sep 22, 2023

Prestige Biologics, a contract development and manufacturing organization (CDMO), announced it has signed a non-binding MOU with Aurigene Pharmaceutical Services, a wholly-owned subsidiary of Dr Reddy’s Laboratories.  The Korea Economic Daily reported that Prestige Biologics will act as the primary manufacturing, packaging, and distribution hub in South Korea for Dr. Reddy’s extensive biopharmaceutical pipeline. Prestige plans to commence technology transfer next month in order to commence production immediately following execution of product-specific supply agreements.

On 12 July 2023, Dr Reddy’s announced that its proposed biosimilar to Genentech/Biogen’s Rituxan®/MabThera® (rituximab) will be reviewed by several global regulatory authorities, including the US FDA, EU EMA and UK MHRA.